Uwe Rix

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger et al. · Blood · 2007 · 655 citations · Full text

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

Jiannong Li, Uwe Rix, Bin Fang et al. · Nature Chemical Biology · 2010 · 281 citations · Full text

Chromatin, Tumor Biology, Biochemistry +12

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Oliver Hantschel, Uwe Rix, Uwe Schmidt et al. · Proceedings of the National Academy of Sciences · 2007 · 278 citations · Full text

Hematological Malignancy, Cancer Research, Chromatin +15

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

Lily L. Remsing Rix, Uwe Rix, Jacques Colinge et al. · Leukemia · 2008 · 275 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Receptor Tyrosine Kinase +8

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

Emir Hadzijusufovic, Karin Albrecht-Schgoer, K. Huber et al. · Leukemia · 2017 · 151 citations · Full text

Endothelial Cell Pathobiology, Inflammation, Vasculitis +12